Alnylam Pharmaceuticals
ALNY
#538
Rank
NZ$73.21 B
Marketcap
NZ$552.02
Share price
-0.40%
Change (1 day)
15.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): NZ$3.13

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$3.14. In 2023 the company made an earnings per share (EPS) of NZ-$6.16 an increase over its 2022 EPS that were of NZ-$16.22.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$3.13
2023NZ-$6.16-62%
2022NZ-$16.2229.03%
2021NZ-$12.57-3.36%
2020NZ-$13.01-8.48%
2019NZ-$14.227.67%
2018NZ-$13.2039.74%
2017NZ-$9.4512.94%
2016NZ-$8.3738.84%
2015NZ-$6.03-32.88%
2014NZ-$8.98259.44%
2013NZ-$2.50-31.25%
2012NZ-$3.63

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.57 300.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$3.61 14.73%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$75.30 2,295.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.79-252.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.27-140.56%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.42-113.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.17-31.11%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.61-80.56%๐Ÿ‡บ๐Ÿ‡ธ USA